Douglas J. Harrison
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Primary Appointment
Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Inpatient Medical Director, Child and Adolescent Center, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Center Medical Director, Children's Cancer Hospital, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1995 | Brown University, Providence, RI, USA, BA, Theater |
Postgraduate Training
| 2006-2007 | Research Fellowship, Pediatric Hematology-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY |
| 2003-2006 | Pediatric Hematology Oncology Clinical Fellowship, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY |
| 2000-2003 | Pediatric Residency, Babies and Children's Hospital of New York/ New York Columbia Presbyterian Medical Center, New York, NY |
Board Certifications
| 2009 | Board Certified in Pediatric Hematology/Oncology |
| 2003 | Board Certified in Pediatrics |
Selected Publications
Peer-Reviewed Articles
- Hingorani P, Roth ME, Wang Y, Zhang W, Gill JB, Harrison DJ, Teicher B, Erickson S, Gatto G, Smith MA, Kolb EA, Gorlick R. ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: A report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther 20(3):535-540, 2021. e-Pub 2020. PMID: 33298592.
- Buszek SM, Ludmir EB, Grosshans DR, McAleer MF, McGovern SL, Harrison DJ, Okcu MF, Chintagumpala MM, Mahajan A, Paulino AC. Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 109(3):718-725, 2021. PMID: 33516439.
- Harrison DJ, Chi YY, Tian J, Hingorani P, Mascarenhas L, McCowage GB, Weigel BJ, Venkatramani R, Wolden SL, Yock TI, Rodeberg DA, Hayes-Jordan AA, Teot LA, Spunt SL, Meyer WH, Hawkins DS, Shulkin BL, Parisi MT. Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer Med 10(3):857-866, 2021. e-Pub 2020. PMID: 33340280.
- Kiany S, Harrison D, Gordon N. The Histone Deacetylase Inhibitor Entinostat/Syndax 275 in Osteosarcoma. Adv Exp Med Biol 1257:75-83, 2020. PMID: 32483732.
Book Chapters
- Harrison DJ. Hematology. In: Step Up To Pediatrics. 1. JB Lippincott: Philadelphia, 2013.
- Harrison DJ. Oncology. In: Step Up To Pediatrics. 1. JB Lippincott: Philadelphia, 2013.
Patient Reviews
CV information above last modified March 28, 2024